News

Dr. Reddy’s Global CEO Leads Delegation to Hybio, Mapping Out International Peptide Partnership

Hybio Pharmaceutical and Institute of Process Engineering, Chinese Academy of Sciences Enter into Strategic Cooperation to Jointly Establish "Innovation Consortium for Industrial Transformation of Hig

On August 20,2025, Shenzhen Hybio Pharmaceutical Co., Ltd. (referred to as "Hybio Pharmaceutical") and the Institute of Process Engineering, Chinese Academy of Sciences (referred to as "IPE-CAS") officially signed a strategic cooperation agreement to jointly build the "Innovation Consortium for Industrial Transformation of High-End Peptide Sustained-Release Preparations". 

Hybio Pharmaceutical and Sunshine Mandi Pharmaceutical Sign a Series of Commercial Agreements, Accelerating the Progress of Weight-Loss Drugs Across the Board

Beijing, August 19, 2025. Shenzhen Hybio Pharmaceutical Co., Ltd. (referred to as "Hybio Pharmaceutical") and Zhejiang Sunshine Mandi Pharmaceutical Co., Ltd. (referred to as "Sunshine Mandi") officially signed a series of commercial documents in Beijing today

Hybio Pharmaceutical and KuCoin Join Forces to Pioneer China’s First RWA Pilot in Innovative Drug Development

On August 4, 2025, Hybio Pharmaceutical and KuCoin, a world-leading digital asset platform, formally signed a strategic cooperation letter of intent. Both parties plan to jointly explore and advance the first RWA (Real World Asset) tokenization pilot project in Hong Kong with "future income rights from innovative drug R&D" as the underlying asset, originating from the Chinese mainland.

Hybio Pharmaceutical and BrightGene Pharmaceutical Enter into Strategic Cooperation to Safeguard Overseas Supply Chains for Innovative Drugs

Hybio Pharmaceutical and iCarbonX Intelligent Peptide Deepen Strategic Cooperation, Signing Two Agreements on Innovative Drug CRDMO Services and Strategic Investment

Academician Ma Guanghui of the Chinese Academy of Sciences and His Delegation Visited Hybio Pharmaceutical to Explore the Development of Long-Acting High-Effect Innovative Peptide Formulations

Hybio Pharmaceutical and iCarbonX-Peptide Sign Joint Development Agreement for GLP-1R/GIPR/GCGR Triple Agonist Peptide Innovative Drug

On May 9, 2025, Shenzhen Hybio Pharmaceutical Co., Ltd. (referred to as "Hybio Pharmaceutical") and Shenzhen iCarbonX Intelligent Peptide Pharmaceutical Technology Co., Ltd. (referred to as "iCarbonX Intelligent Peptide") formally signed a joint development agreement for GLP-1R/GIPR/GCGR triple agonist peptide innovative drugs and held a grand signing ceremony.

Hybio Pharmaceutical, Hybio Health, and BMC Medical Sign Strategic Cooperation Agreement to Build a New Ecosystem for Sleep Health Management

On May 12, Hybio Pharmaceutical, Hybio Health, and BMC Medical signed a strategic cooperation agreement. The three parties will engage in comprehensive strategic cooperation in the field of sleep health across multiple dimensions, including scenario application, technology synergy, scientific research collaboration, market synergy, and user reach.

Hybio Pharmaceutical and Sinopharm CNCM Sign Strategic Cooperation Agreement to Explore New Paths for Innovative Drug R&D

Hybio Pharmaceutical and Huawei Cloud Sign Comprehensive Cooperation Agreement, Focusing on "AI-powered Drug Discovery" to Promote Intelligent Upgrades in the Pharmaceutical Industry

On April 27, 2025, Shenzhen Hybio Pharmaceutical Co., Ltd. and Huawei Cloud Computing Technologies Co., Ltd. held a signing ceremony for a comprehensive cooperation agreement at Huawei's Bantian Base in Shenzhen. 

Li Jie, Director of Shenzhen Guanlan Customs, And His Entourage Visited Hybio Pharmaceutical to Conduct Research and Assist the Company in Its New Development

On April 21, 2025, a research team led by Li Jie, Director of Shenzhen Guanlan Customs, paid a visit to Hybio Pharmaceutical for investigation. 

Mr. Riad Mishlawi, CEO of Hybio Pharmaceutical's Global Partner Hikma, Visits with His Executive Team to Deepen Long-Term Cooperation

Hybio Pharmaceutical's 2025 First Quarter Performance Forecast

Hybio Pharmaceutical's 2025 First Quarter Performance Forecast: Revenue and Profit Achieve Double-Digit Growth, GLP-1's International Expansion Is Just the Beginning, and a Formulation Matrix is "Fired on All Cylinders."

Hybio Pharmaceutical Sincerely Invites Global Partners to Gather at 2025 DCAT Week

In 2025, DCAT Week will be grandly held in New York, USA, from March 17th to 20th (local time). It is Hybio Pharmaceutical’s honor to participate in this event and meet with global pharmaceutical industry partners at the Jacob K. Javits Convention Center in New York.